Advertisement

Pharmaceutical Chemistry Journal

, Volume 46, Issue 4, pp 234–240 | Cite as

Development of effective pilot-scale technology for producing N,N-bis-met-histone H1.3 used for lymphoma treatment

  • D. A. Gusarov
  • I. V. Sokolova
  • V. D. Gusarova
  • E. A. Evteeva
  • T. V. Vorob’eva
  • S. A. Kosarev
  • E. D. Shibanova
  • D. I. Bairamashvili
Article

Much attention is presently devoted to the treatment of lymphoma using monoclonal antibodies. Unfortunately, preparations such as Rituximab (MabThera) are not produced in the Russian Federation and must be imported from abroad. It was shown that H1-type histones with activities similar to that of Rituximab can be used for such therapy. We have developed an pilot-scale technology for the production of recombinant N,N-bis-met-histone H1.3. The activity and purity of the obtained preparation were demonstrated in several tests. The produced amount of active pharmaceutical ingredient was sufficient to start clinical trials in Russia.

Key words

N,N-bis-met-histone H1.3 lymphoma chromatography technology 

References

  1. 1.
    A. Fritz, C. Percy, A. Jack, et al. (eds.), International Classification of Diseases for Oncology, Third Ed., World Health Organization, Geneva (2000).Google Scholar
  2. 2.
    P. Stashenko, L. M. Nadler, R. Hardy, and S. F. Schlossman, J. Immunol., 125, 1678 – 1685 (1980).PubMedGoogle Scholar
  3. 3.
    J. Ernst, H. Li, H. S. Kim, et al., Biochemistry, 44, 15150 – 15158 (2005).PubMedCrossRefGoogle Scholar
  4. 4.
    V. M. Moiseenko, Praktich. Onkol., 3(4), 253 – 261 (2002).Google Scholar
  5. 5.
    M. Zeppezauer, H.-P. Leinenbach, R. Class, and C. Fassbender, “Use of histones for the production of medicines,” Eur. Pat. EP 0973541 (2000).Google Scholar
  6. 6.
    D. A. Gusarov, Biofarm. Zh., 2(4), 8 – 13 (2010).Google Scholar
  7. 7.
    P. Gross, H. Jornvall, M. Thiry, et al., “Bis-Met Histone,”World Intellectual Property Organization Patent Application, WO 2008 / 122434 A1. 2008.Google Scholar
  8. 8.
    Laboratory regulation No. LR 02699487 – 13 – 01 (2009).Google Scholar
  9. 9.
    J. King and U. K. Laemmli, J. Mol. Biol., 75(2), 315 – 324 (1973).PubMedCrossRefGoogle Scholar
  10. 10.
    Yu. S. Ryabko, O. V. Lukin, E. N. Shepel’, et al., Biofarm. Zh., 1(1), 34 – 37 (2009).Google Scholar
  11. 11.
    W. Albig, D. M. Runge, M. Kratzmeier, and D. Doenecke, FEBS Lett., 435, 425 – 450 (1998).CrossRefGoogle Scholar
  12. 12.
  13. 13.
    M. Kratzmeier, W. Albig, T. Meergans, and D. Doenecke, Biochem. J., 337, 319 – 327 (1999).PubMedCrossRefGoogle Scholar
  14. 14.
    D. A. Gusarov, V. A. Lasman, S. A. Kosarev, et al., Biofarm. Zh., 2(1), 42 – 48 (2010).Google Scholar
  15. 15.
    G. L. Volkov, S. P. Gavrilyuk, V. V. Skalka, et al., Biofarm. Zh., 2(2), 24 – 31 (2010).Google Scholar
  16. 16.
    D. A. Gusarov, Biofarm. Zh., 1(3), 10 – 17 (2009).Google Scholar
  17. 17.
    N. S. Brykova, N. A. Bragina, D. A. Gusarov, and D. I. Bairamashvili, Biofarm. Zh., 2(4), 25 – 31 (2010).Google Scholar
  18. 18.
    D. A. Gusarov, V. A. Lasman, A. F. Mironov, and D. I. Bairamashvili, Biofarm. Zh., 1(3), 30 – 35 (2009).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2012

Authors and Affiliations

  • D. A. Gusarov
    • 1
  • I. V. Sokolova
    • 1
  • V. D. Gusarova
    • 1
  • E. A. Evteeva
    • 1
  • T. V. Vorob’eva
    • 1
  • S. A. Kosarev
    • 1
  • E. D. Shibanova
    • 1
  • D. I. Bairamashvili
    • 1
  1. 1.Shemyakin – Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussia

Personalised recommendations